Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Yoshiki Hirooka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9639-7425; OpenAlex author ID A5048728798. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
119
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 27

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  4. Efficacy of 1-Kestose Supplementation in Patients with Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Pilot Study. Last author DOI 10.3390/nu16172889↗
  5. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  6. Changes in intestinal bacteria and imbalances of metabolites induced in the intestines of pancreatic ductal adenocarcinoma patients in a Japanese population: a… Last author DOI 10.1080/00365521.2022.2114812↗
  7. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less Co-author DOI 10.21203/rs.3.rs-3014153/v1↗
  8. Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/diagnostics13020215↗
  9. Comparison of contrast-enhanced transabdominal ultrasonography following endoscopic ultrasonography with GD-EOB-DTPA-enhanced MRI for the sequential diagnosis … Co-author DOI 10.1002/jhbp.1097↗
  10. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  11. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  12. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.12.022↗
  13. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Co-author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  14. Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000001579↗
  15. Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography. Co-author DOI 10.1186/s12876-020-01228-9↗
  16. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  17. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Last author DOI 10.1159/000492388↗
  18. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  19. ATAD2 is associated with malignant characteristics of pancreatic cancer cells. Co-author DOI 10.3892/ol.2019.9960↗
  20. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  21. Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. First author DOI 10.1111/jgh.13967↗
  22. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-4453-z↗
  23. Plasma Kallikrein-Dependent Transforming Growth Factor-β Activation in Patients With Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000736↗
  24. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  25. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. Last author DOI 10.1111/jgh.13172↗
  26. Treatment with near-infrared radiation promotes apoptosis in pancreatic cancer cells. Co-author DOI 10.3892/ol.2015.3399↗
  27. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Last author DOI 10.1007/s00280-010-1531-6↗

Closest collaborators

The 25 strongest of 119 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eizaburo Ohno · 15 shared papers, 2011–2024 · strength 1.53
  2. Hiroki Kawashima · 13 shared papers, 2011–2023 · strength 1.27
  3. Takuya Ishikawa · 11 shared papers, 2018–2023 · strength 1.21
  4. Atsushi Masamune · 9 shared papers, 2016–2026 · strength 0.98
  5. Tsutomu Fujii · 8 shared papers, 2016–2026 · strength 0.80
  6. Senju Hashimoto · 7 shared papers, 2011–2024 · strength 0.71
  7. Sohei Satoi · 6 shared papers, 2016–2026 · strength 0.67
  8. Tadashi Iida · 5 shared papers, 2021–2023 · strength 0.66
  9. Michiaki Unno · 5 shared papers, 2016–2026 · strength 0.58
  10. Yasuyuki Mizutani · 4 shared papers, 2022–2023 · strength 0.56
  11. Hidemi Goto · 8 shared papers, 2011–2019 · strength 0.50
  12. Kazunori Nakaoka · 3 shared papers, 2023–2024 · strength 0.50
  13. Tamotsu Kuroki · 5 shared papers, 2016–2025 · strength 0.49
  14. Hisato Igarashi · 5 shared papers, 2016–2025 · strength 0.49
  15. Hidetoshi Eguchi · 5 shared papers, 2016–2025 · strength 0.49
  16. Hiroki Yamaue · 5 shared papers, 2016–2025 · strength 0.49
  17. Masaji Tani · 5 shared papers, 2016–2025 · strength 0.49
  18. Yoshifumi Takeyama · 3 shared papers, 2023–2026 · strength 0.47
  19. Mitsuhiro Fujishiro · 4 shared papers, 2020–2022 · strength 0.45
  20. Satoshi Hirano · 3 shared papers, 2020–2026 · strength 0.42
  21. Tomohisa Yamamoto · 3 shared papers, 2020–2025 · strength 0.37
  22. Shuji Suzuki · 2 shared papers, 2025–2026 · strength 0.34
  23. Masamichi Hayashi · 3 shared papers, 2018–2026 · strength 0.31
  24. Kazuichi Okazaki · 3 shared papers, 2019–2025 · strength 0.31
  25. Yosuke Inoue · 2 shared papers, 2023–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.